
Halozyme Therapeutics
Founded Year
1998Stage
IPO | IPOTotal Raised
$20.27MDate of IPO
5/10/2007Market Cap
5.24BStock Price
39.69About Halozyme Therapeutics
Halozyme Therapeutics is a biopharmaceutical company that focuses on improving patient experiences and outcomes through innovative drug delivery technologies. The company's main offerings include the development of new drugs and the provision of disruptive solutions such as the ENHANZE® technology, which facilitates the delivery of injected drugs and fluids, potentially reducing treatment time. Halozyme primarily serves the biopharmaceutical industry, partnering with leading companies to develop and commercialize products that improve patient lives. It was founded in 1998 and is based in San Diego, California.
Loading...
Loading...
Halozyme Therapeutics Patents
Halozyme Therapeutics has filed 75 patents.
The 3 most popular patent topics include:
- clusters of differentiation
- proteins
- hepatotoxins

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/2/2020 | 8/15/2023 | Psychiatric diagnosis, Gene expression, Therapy, Nitriles, Antibiotics | Grant |
Application Date | 10/2/2020 |
---|---|
Grant Date | 8/15/2023 |
Title | |
Related Topics | Psychiatric diagnosis, Gene expression, Therapy, Nitriles, Antibiotics |
Status | Grant |
Latest Halozyme Therapeutics News
Nov 27, 2023
Halozyme to Present at Upcoming Investor Conferences November 27, 2023 at 08:01 am EST Share SAN DIEGO, Nov. 27, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of the senior leadership team are scheduled to present and host investor meetings at the following investor conferences. Details on the presentations are as follow: Event: Presenter: Format: Presentation Date: Location: Presenter: Format: Presentation Date: Location: Miami, FL A live audio webcast of the presentations will be available in the Investor Relations section of the Company's website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in seven commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED® and TLANDO® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter. Contacts:
Halozyme Therapeutics Frequently Asked Questions (FAQ)
When was Halozyme Therapeutics founded?
Halozyme Therapeutics was founded in 1998.
Where is Halozyme Therapeutics's headquarters?
Halozyme Therapeutics's headquarters is located at 11388 Sorrento Valley Road, San Diego.
What is Halozyme Therapeutics's latest funding round?
Halozyme Therapeutics's latest funding round is IPO.
How much did Halozyme Therapeutics raise?
Halozyme Therapeutics raised a total of $20.27M.
Who are the investors of Halozyme Therapeutics?
Investors of Halozyme Therapeutics include Roche Venture Fund, Ritchie Capital Management, Colt Ventures, Cimarron Biomedical Investors, SuRo Capital and 3 more.
Loading...
Loading...